C4 Therapeutics Inc’s recently made public that its Chief Business Officer Boyle Scott N unloaded Company’s shares for reported $2107.0 on Feb 18 ’25. In the deal valued at $3.15 per share,669 shares were sold. As a result of this transaction, Boyle Scott N now holds 107,805 shares worth roughly $0.17 million.
Then, Boyle Scott N sold 490 shares, generating $1,544 in total proceeds. Upon selling the shares at $3.15, the Chief Business Officer now owns 110,842 shares.
Before that, Salter Malcolm bought 13,000 shares. C4 Therapeutics Inc shares valued at $54,532 were divested by the Director at a price of $4.19 per share.
Wells Fargo upgraded its C4 Therapeutics Inc [CCCC] rating to an Overweight from a an Equal weight in a research note published on December 19, 2024; the price target was increased to $12 from $8. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Equal-weight”‘ rating. JP Morgan also remained covering CCCC and has increased its forecast on January 29, 2024 with a “Neutral” recommendation from previously “an Underweight” rating. Stifel revised its rating on December 13, 2023. It rated CCCC as “a Buy” which previously was an “a Hold”.
Price Performance Review of CCCC
On Monday, C4 Therapeutics Inc [NASDAQ:CCCC] saw its stock jump 5.19% to $1.62. Over the last five days, the stock has gained 15.71%. C4 Therapeutics Inc shares have fallen nearly -55.00% since the year began. Nevertheless, the stocks have fallen -74.96% over the past one year. While a 52-week high of $7.66 was reached on 01/06/25, a 52-week low of $1.09 was recorded on 04/17/25. SMA at 50 days reached $1.9856, while 200 days put it at $4.3775.
Levels Of Support And Resistance For CCCC Stock
The 24-hour chart illustrates a support level at 1.5433, which if violated will result in even more drops to 1.4667. On the upside, there is a resistance level at 1.6833. A further resistance level may holdings at 1.7467. The Relative Strength Index (RSI) on the 14-day chart is 50.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.2279, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 18.46%. Stochastics %K at 76.92% indicates the stock is a holding.
How much short interest is there in C4 Therapeutics Inc?
A steep rise in short interest was recorded in C4 Therapeutics Inc stocks on 2025-04-15, dropping by -0.45 million shares to a total of 7.73 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 8.17 million shares. There was a decline of -5.76%, which implies that there is a negative sentiment for the stock.
